Pipelines
At Protheragen, we specialize in advancing MyD88-targeted therapeutics through strategic out-licensing and co-development partnerships. Our team is dedicated to translating cutting-edge scientific discoveries in innate immune signaling into transformative therapies for oncology, inflammatory disorders, and autoimmune diseases. The MyD88-targeted pipeline features preclinical-stage programs demonstrating exceptional target engagement and therapeutic potential across multiple indications.
If you are intrigued by our project pipeline and technology platform, please don't hesitate to contact us for further details.
| Pipeline | Indication | Preclinical (API) | Preclinical (Formulation) | IND (US & China) | Phase I Clinic | Phase II Clinic | Phase III Clinic |
|---|---|---|---|---|---|---|---|
| PRTG160S Ointment | Psoriasis | ||||||
| Eczema | |||||||
| Nervous dermatitis | |||||||
| PRTG160S IV Injectable | Acute myocardial infarction | ||||||
| Acute cerebral infarction | |||||||
| Organ transplantation | |||||||
| Limb replantation | |||||||
| PRTG160S SR tablet | Colitis/colon cancer | ||||||
| Hepatitis/cirrhosis/liver cancer | |||||||
| Gastritis/gastric cancer | |||||||
| PRTG160S organ preservation | Organ preservation solution | ||||||
| PRTG160X oral preparation | Anti-transplant rejection | ||||||
| PRTG160S eye drops | Xerophthalmia | ||||||
| PRTG160X oral preparation | Type I diabetes | ||||||
| Type II diabetes | |||||||
| Systemic lupus erythematosus | |||||||